2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11D.05 EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy

P4.11D.05 EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy

Pdf Summary

Summary Not Available

Asset Subtitle

Lifeng Wang

Meta Tag

Speaker Lifeng Wang

Topic Metastatic NSCLC – Immunotherapy